Who Owns MiNK Therapeutics Stock?
NASDAQ: INKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:11 AM ET
Ownership breakdown
- Held by institutions
- 4.00%
- Held by insiders
- 59.37%
- Institutional holders
- 30
- Institutions 4.0%
- Insiders 59.4%
- Public and other 36.6%
Who owns MiNK Therapeutics stock?
Institutional investors own about 4.0% of MiNK Therapeutics's shares, spread across 30 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 59.37% of INKT.
The largest institutional holders are Vanguard Capital Management LLC (1.35%), DnB Asset Management AS (1.08%) and Longbow Finance Sa (0.33%). Together, the top 10 institutions control 4.0% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their INKT positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of INKT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vanguard Capital Management LLC | 68.66K | 1.35% | +15.7% |
| DnB Asset Management AS | 55.14K | 1.08% | +100.0% |
| Longbow Finance Sa | 16.67K | 0.33% | 0.0% |
| Geode Capital Management, LLC | 15.57K | 0.31% | -10.2% |
| Citadel Advisors Llc | 15.44K | 0.30% | +100.0% |
| Blackrock Inc. | 13.38K | 0.26% | +115.7% |
| Vanguard Fiduciary Trust Co | 8.29K | 0.16% | 0.0% |
| UBS Group AG | 4.88K | 0.10% | -67.9% |
| Steward Partners Investment Advisory, LLC | 2.00K | 0.04% | 0.0% |
| US BANCORP \DE\ | 2.00K | 0.04% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of INKT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 53.07K | 1.04% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 15.38K | 0.30% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 6.79K | 0.13% |
| iShares Trust-iShares Micro-Cap ETF | 6.69K | 0.13% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 2.89K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 1.88K | 0.04% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 1.53K | 0.03% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 445 | 0.01% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 208 | 0.00% |
Frequently asked questions
Who is the largest shareholder of MiNK Therapeutics?
Vanguard Capital Management LLC is the largest institutional shareholder of INKT, owning 1.35% of shares outstanding (68.66K shares) as of its latest 13F filing.
What percentage of MiNK Therapeutics is owned by institutions?
Institutions own about 4.0% of INKT shares and 9.8% of the public float.
How much of MiNK Therapeutics do insiders own?
Insiders, such as officers and directors, own about 59.37% of INKT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.